Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer

  • Authors:
    • Ana Ines Cases
    • Takao Ohtsuka
    • Hideyo Kimura
    • Biao Zheng
    • Koji Shindo
    • Yoshinao Oda
    • Kazuhiro Mizumoto
    • Masafumi Nakamura
    • Masao Tanaka
  • View Affiliations

  • Published online on: July 20, 2015     https://doi.org/10.3892/or.2015.4138
  • Pages: 1717-1725
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glucagon-like peptide 1 (GLP-1) induces insulin secretion and proliferation of pancreatic β-cells, and inhibits their apoptosis through the GLP-1 receptor (GLP-1R), thus providing a foundation for using GLP-1-based therapies for the treatment of type 2 diabetes. However, doubts have emerged regarding the drug safety of these therapies. We investigated the potential role of GLP-1R in pancreatic ductal adenocarcinoma (PDAC). GLP-1R expression was semi-quantitatively evaluated by immunohistochemistry in 48 PDAC samples, and its correlations with clinicopathological features were investigated. CFPAC-1 cells were used for GLP-1R knockdown to evaluate its effects on cell proliferation, migration and invasion. GLP-1R expression was positive in 23 tumors and negative in 25 tumors. No correlations were found between GLP-1R expression status and clinicopathological characteristics. Furthermore, GLP-1R expression status did not affect the patient prognosis (P=0.74). The majority of lymph node metastases (11 of 15 samples examined; 73%) were positive for GLP-1R expression. Immunoreactivity for GLP-1R was also noted in sites of perineural and lymphovascular invasion. GLP-1R knockdown significantly reduced the proliferation, migration and invasion of CFPAC-1 cells (P<0.05). In conclusion, although GLP-1R is not an independent prognostic factor in PDAC patients, it appears to have some implications for PDAC metastatic ability.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 34 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cases AI, Ohtsuka T, Kimura H, Zheng B, Shindo K, Oda Y, Mizumoto K, Nakamura M and Tanaka M: Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Oncol Rep 34: 1717-1725, 2015
APA
Cases, A.I., Ohtsuka, T., Kimura, H., Zheng, B., Shindo, K., Oda, Y. ... Tanaka, M. (2015). Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Oncology Reports, 34, 1717-1725. https://doi.org/10.3892/or.2015.4138
MLA
Cases, A. I., Ohtsuka, T., Kimura, H., Zheng, B., Shindo, K., Oda, Y., Mizumoto, K., Nakamura, M., Tanaka, M."Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer". Oncology Reports 34.4 (2015): 1717-1725.
Chicago
Cases, A. I., Ohtsuka, T., Kimura, H., Zheng, B., Shindo, K., Oda, Y., Mizumoto, K., Nakamura, M., Tanaka, M."Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer". Oncology Reports 34, no. 4 (2015): 1717-1725. https://doi.org/10.3892/or.2015.4138